AR132774A1 - Composiciones farmacéuticas - Google Patents

Composiciones farmacéuticas

Info

Publication number
AR132774A1
AR132774A1 ARP240101316A ARP240101316A AR132774A1 AR 132774 A1 AR132774 A1 AR 132774A1 AR P240101316 A ARP240101316 A AR P240101316A AR P240101316 A ARP240101316 A AR P240101316A AR 132774 A1 AR132774 A1 AR 132774A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical compositions
dcpa
mcc
pyrrolo
pyrimidin
Prior art date
Application number
ARP240101316A
Other languages
English (en)
Inventor
Husban Farhan Abdel Karim Mohammad Al
Tomos Rees Morgan
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR132774A1 publication Critical patent/AR132774A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente memoria descriptiva se relaciona con composiciones farmacéuticas que comprenden el Compuesto [I] ((S)-4-amino-N-(1-(4-clorofenil)-3-hidroxipropil)-1-(7H-pirrolo[2,3-d]pirimidin-4-il)piperidina-4-carboxamida), celulosa microcristalina (MCC) y fosfato de dicalcio anhidro (DCPA), por ejemplo, en comprimidos con propiedades de liberación inmediata.
ARP240101316A 2023-05-26 2024-05-24 Composiciones farmacéuticas AR132774A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP23175788 2023-05-26

Publications (1)

Publication Number Publication Date
AR132774A1 true AR132774A1 (es) 2025-07-30

Family

ID=86605004

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP240101316A AR132774A1 (es) 2023-05-26 2024-05-24 Composiciones farmacéuticas

Country Status (15)

Country Link
EP (1) EP4719359A1 (es)
JP (1) JP2026518000A (es)
KR (1) KR20260016534A (es)
CN (1) CN121175036A (es)
AR (1) AR132774A1 (es)
AU (1) AU2024279893A1 (es)
CL (1) CL2025003668A1 (es)
CO (1) CO2025018521A2 (es)
CR (1) CR20250538A (es)
DO (1) DOP2025000289A (es)
IL (1) IL324773A (es)
MX (1) MX2025014102A (es)
PE (1) PE20260438A1 (es)
TW (1) TW202510865A (es)
WO (1) WO2024245953A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0818533B8 (pt) 2007-10-11 2021-05-25 Astrazeneca Ab composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
WO2022147519A1 (en) * 2021-01-04 2022-07-07 Teva Pharmaceuticals International Gmbh Solid state forms of capivasertib and process for preparation thereof
CN119278041A (zh) * 2022-03-31 2025-01-07 阿斯利康(瑞典)有限公司 用于治疗癌症的与akt抑制剂组合的表皮生长因子受体(egfr)酪氨酸激酶抑制剂

Also Published As

Publication number Publication date
MX2025014102A (es) 2026-01-07
CN121175036A (zh) 2025-12-19
TW202510865A (zh) 2025-03-16
CO2025018521A2 (es) 2026-01-13
IL324773A (en) 2026-01-01
PE20260438A1 (es) 2026-02-19
WO2024245953A1 (en) 2024-12-05
EP4719359A1 (en) 2026-04-08
DOP2025000289A (es) 2026-01-15
AU2024279893A1 (en) 2026-01-22
CR20250538A (es) 2026-04-21
JP2026518000A (ja) 2026-06-02
KR20260016534A (ko) 2026-02-03
CL2025003668A1 (es) 2026-03-13

Similar Documents

Publication Publication Date Title
CL2008003023A1 (es) (s)-4-amino-n-(1-(4-clorofenil)-3-hidroxipropil)-1-(7h-pirrolo[2,3-d]pirimidin-4-il)piperidina-4-carboxamida, inhibidor de la proteina quinasa b; procedimiento de preparacion; compuestos intermediarios; composicion farmacéutica que comprende dicho compuesto; y uso para el tratamiento del cancer.
UY39296A (es) Azaquinolonas sustituidas inhibidoras de parp y composiciones farmacéuticas que las contienen
AR116797A1 (es) Sal de tosilato de pirrolo[2,3-d]pirimidina, forma cristalina de la misma y proceso de fabricación e intermediario al mismo
UY29410A1 (es) Composiciones farmacéuticas en base a metilamidas del ácido 4-(4-/-3(-4-cloro-3-trifluorometifenil)ureido)fenoxi)piridin-2-carboxílico, procedimiento de preparación y aplicaciones.
GT200600246A (es) Formulacion de 1-[(3-hidroxi-adamant-1-ilamino)-acetil]-pirrolidin-2(s)-carbonitrilo de liberacion modificada
CO6150163A2 (es) Composiciones adecuadas para administracion oral que comprende un derivado de triazolo [4,5-d] pirimidina
ECSP11010960A (es) Formulación farmacéutica 514
MX2024014861A (es) Inhibidor de la prmt5 de tres anillos fusionados que contiene nitrogeno, y metodo de preparacion del mismo y uso farmaceutico del mismo
AR065802A1 (es) Formulaciones de comprimidos que contienen sales de 8- [( 1- ( 3,5- bis- (trifluorometil) fenil) -etoxi ) - metil) -8- fenil -1, 7- diaza- spiro [ 4,5] decan -2- ona y comprimidos elaborados a partir de estas
PE20080698A1 (es) Composiciones farmaceuticas de inhibidores de dpp iv
PE20240050A1 (es) Inhibidores de cdk2 y metodos de uso de los mismos
UY39094A (es) Composición farmacéutica que comprende compuesto derivado de bencimidazol
MY175052A (en) Crystalline forms of (s) -4-amino-n- (1- (4 - chlorophenyl) - 3 - hydroxypropyl) -1- (7h - pyrrolo [2, 3-d] pyrimidi n-4-yl) piperidine-4-carboxamide
CL2024001679A1 (es) Formas en estado sólido de un inhibidor de fgfr
UY29325A1 (es) Nuevos derivados de 2 - amino-piridina
MX2024008413A (es) Compuestos macrocíclicos y uso como inhibidores de cinasas.
CO2025018521A2 (es) Composiciones farmacéuticas
MX2023006284A (es) Composicion farmaceutica de agonistas duales de glp-1/glp-2.
CO2022016378A2 (es) Formulaciones farmacéuticas
UY29361A1 (es) Pirroles e imidazoles sustituídos, composiciones que los contienen, procedimiento de fabricación y utilización
DOP2019000099A (es) Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina y usos de los mismos
CO2021014253A2 (es) Formulación de tableta vaginal
AR043173A1 (es) Uso de dipiridamol en combinacion con acido acetilsalicilico y un antagonista de angiotensina ii para la prevencion de accidente cerebrovascular
PE20070084A1 (es) Proceso para la sintesis de 5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-bencenamina
ECSP23089201A (es) Nueva formulación para inyección que comprende 1-(5-(2,4-difluorofenil)-1-((3-fluorofenil)sulfonil)-4-metoxi-1h-pirrol-3-il)-n-metilmetanamina